Keyphrases
Sarcoma
84%
Soft Tissue Sarcoma
73%
Tumor
59%
Phase II Study
40%
Synovial Sarcoma
40%
Cancer Types
39%
Phase II Trial
38%
Doxorubicin
37%
Cancer Genome Atlas
33%
Leiomyosarcoma
25%
Osteosarcoma
23%
Advanced Soft Tissue Sarcoma
21%
Progression-free Survival
21%
Clinical Trials
20%
Adverse Events
20%
Metastatic Soft Tissue Sarcoma
19%
Malignant Peripheral Nerve Sheath Tumor (MPNST)
18%
High-risk Human Papillomavirus (HR-HPV)
17%
In Cancer
17%
Olaratumab
17%
Overall Survival
17%
Round Cell Liposarcoma
17%
Myxoid
17%
Chemotherapy
17%
Dacarbazine
17%
Confidence Interval
16%
Argininosuccinate Synthetase
16%
Pan-cancer
16%
Radiation Therapy
15%
ADI-PEG20
15%
Pazopanib
15%
Dedifferentiated Liposarcoma (DDLPS)
15%
Metastatic Sarcoma
14%
Arginine
14%
Clinical Outcomes
14%
Arginine Starvation
13%
Patient-derived Xenograft
13%
Human Cancer
12%
Angiosarcoma
12%
Liposarcoma
12%
Partial Response
12%
Gemcitabine
12%
Duration of Response
12%
Response Evaluation Criteria in Solid Tumors (RECIST)
12%
Pan-cancer Analysis
11%
Comprehensive Characterization
11%
Molecular Characterization
11%
Desmoid Tumor
11%
Docetaxel
11%
Glyceraldehyde-3-phosphate Dehydrogenase
11%
Medicine and Dentistry
Connective Tissue Cancer
100%
Soft Tissue Sarcoma
79%
Neoplasm
54%
Malignant Neoplasm
38%
Clinical Trial
32%
Synovial Sarcoma
31%
Cancer
26%
Progression Free Survival
25%
Diseases
24%
Leiomyosarcoma
24%
Adverse Event
23%
Overall Survival
23%
Arginine
22%
Doxorubicin
19%
The Cancer Genome Atlas
16%
Liposarcoma Cell
16%
Osteosarcoma
15%
Arm
15%
Angiosarcoma
15%
Immunotherapy
14%
Radiation Therapy
14%
Dacarbazine
14%
Gastrointestinal Stromal Tumor
14%
Cancer Types
13%
Pazopanib
12%
T Cell
11%
Liposarcoma
11%
Desmoid Tumor
11%
Biological Marker
11%
Ifosfamide
10%
Pembrolizumab
9%
Targeted Therapy
9%
Trabectedin
9%
Malignant Peripheral Nerve Sheath Tumor
9%
Olaratumab
9%
Gemcitabine
8%
Cell Signaling Pathway
8%
Docetaxel
8%
Dedifferentiated Liposarcoma
7%
Argininosuccinate Synthase
7%
Systemic Therapy
7%
Anthracycline
7%
HLA-A
7%
Ipilimumab
6%
Nivolumab
6%
Placebo
6%
Breast Cancer
6%
Carcinogenesis
6%
Ewing Sarcoma
6%
Neutropenia
6%
Pharmacology, Toxicology and Pharmaceutical Science
Soft Tissue Sarcoma
68%
Connective Tissue Cancer
53%
Neoplasm
45%
Malignant Neoplasm
42%
Doxorubicin
37%
Progression Free Survival
37%
Adverse Event
27%
Diseases
25%
Overall Survival
24%
Leiomyosarcoma
19%
Synovial Sarcoma
18%
Clinical Trial
18%
Chemotherapy
18%
Olaratumab
17%
Dacarbazine
17%
Arginine
17%
Liposarcoma
16%
Pazopanib
15%
Biological Marker
14%
Gemcitabine
12%
Osteosarcoma
12%
Placebo
11%
Angiosarcoma
11%
Rapamycin
11%
Docetaxel
11%
Human Papillomavirus
11%
Dedifferentiated Liposarcoma
11%
Trabectedin
9%
Solid Malignant Neoplasm
9%
Malignant Peripheral Nerve Sheath Tumor
8%
Gastrointestinal Stromal Tumor
7%
Pharmacokinetics
7%
Monotherapy
7%
Head and Neck Squamous Cell Carcinoma
6%
Neutropenia
6%
Phase II Trials
6%
Argininosuccinate Synthase
6%
Cardiotoxicity
6%
Anthracycline
6%
Proteinase
6%
Perivascular Epithelioid Cell Tumour
5%
Ovary Cancer
5%
Atezolizumab
5%
Desmoid Tumor
5%
Palbociclib
5%
Evofosfamide
5%
Ipilimumab
5%
Nivolumab
5%
Clinical Study
5%
Pexidartinib
5%